medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma

Chinchilla-López P, Qi X, Yoshida EM, Méndez-Sánchez N

Language: English
References: 11
Page: 328-330
PDF size: 106.43 Kb.


ABSTRACT

The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferonbased therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.


REFERENCES

  1. Davis G, Albright J, Cook S, Rosenberg D. Projecting Future Complications of Chronic Hepatitis C in the United States. Liver Transplant 2003: 331-8.

  2. Méndez-Sánchez N, Villa A, Chávez-Tapia N, Ponciano-Rodríguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 1: 52-5.

  3. Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronichepatitisCpatientsachievingasustainedvirologicalresponse to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol 2014; 49: 1504-13.

  4. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D2, Mills PR, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the generalpopulation. J Hepatol 2017; 1: 19-27.

  5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA 2012; 24: 2584-93.

  6. Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma patients with hepatitis C in Canada. J Hepatol 2017; 66: 504-13.

  7. Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016; 65: 861-2.

  8. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with directacting antivirals. J Hepatol 2017 Feb 2. pii: S0168- 8278(17)30053-3. doi: 10.1016/j.jhep.2017.01.020.

  9. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi F, et al. Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals. J Hepatol 2016; 30303-8.

  10. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016; 65: 719-26.

  11. Jacobson I, Lim J, Fried M. Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017 doi: 10.1053/j.gastro.2017.03.018.




2020     |     www.medigraphic.com